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Purpose: To estimate dose–response relationship using dynamic quantitative 99mTc-pertechnate scintigraphy in
head-neck cancer patients treated with parotid-sparing conformal radiotherapy.
Methods: Dynamic quantitative pertechnate salivary scintigraphy was performed pre-treatment and subsequently
periodically after definitive radiotherapy. Reduction in salivary function following radiotherapy was quantified by
salivary excretion fraction (SEF) ratios. Dose–response curves were modeled using standardized methodology to
calculate tolerance dose 50 (TD50) for parotid glands.
Results: Salivary gland function was significantly affected by radiotherapy with maximal decrease in SEF ratios at
3-months, with moderate functional recovery over time. There was significant inverse correlation between SEF ratios
and mean parotid doses at 3-months (r = −0.589, p < 0.001); 12-months (r = −0.554, p < 0.001); 24-months (r = −0.371,
p = 0.002); and 36-months (r = −0.350, p = 0.005) respectively. Using a post-treatment SEF ratio <45% as the scintigraphic
criteria to define severe salivary toxicity, the estimated TD50 value with its 95% confidence interval (95% CI) for the
parotid gland was 35.1Gy (23.6-42.6Gy), 41.3Gy (34.6-48.8Gy), 55.9Gy (47.4-70.0Gy) and 64.3Gy (55.8-70.0Gy) at 3, 12, 24,
and 36-months respectively.
Conclusions: There is consistent decline in parotid function even after conformal radiotherapy with moderate recovery
over time. Dynamic quantitative pertechnate scintigraphy is a simple, reproducible, and minimally invasive test of major
salivary gland function.
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Definitive (chemo) radiotherapy is the contemporary
standard of care in the non-surgical management of
head and neck squamous cell carcinoma (HNSCC) [1,2].
The salivary glands are often incidentally irradiated dur-
ing comprehensive irradiation of the head-neck cancers
resulting in xerostomia that can adversely affect health-
related quality-of-life (QOL) [3-5]. Xerostomia may re-
sult in poor oro-dental hygiene, altered taste sensation,
and pain leading to difficulty in speaking, chewing and
swallowing [6]. Xerostomia can be defined and graded
[6,7] both subjectively according to patient’s symptoms
(severity of dryness and/or response on stimulation) as
well as objectively using quantified saliva production or
excretion (salivary flow and/or scintigraphy). Stimulated
salivary production is largely derived from the parotid
glands while resting or unstimulated saliva is mostly pro-
duced by submandibular, sublingual, and various minor
salivary glands [8]. Traditionally, salivary gland function
has been assessed objectively by flow-rate measurements
[9-11]. This can be performed at rest (unstimulated) or
in response to administration of a sialogogue (post-
stimulation). Collection of secretion from each parotid
duct orifice via a cannula is the most common method
of assessing individual parotid gland function. However,
cannulation is an invasive procedure associated with a
steep learning curve necessitating technical skill and ex-
pertise. It can at times be quite difficult and challenging
[11], particularly in the post-treatment setting. Alterna-
tively, whole mouth salivary function can be assessed by
asking the patient to produce as much saliva as possible
within a given period of time. Such measurementscan be
uncertain and variable, with standard deviation of 20-
30% reported for whole-mouth measurements [10]. In
recent times, high-precision radiotherapy techniques
such as three-dimensional conformal radiotherapy
(3D-CRT) and intensity-modulated radiation therapy
(IMRT) have gained immense popularity in HNSCC.
IMRT produces highly conformal dose distributions with
resultant substantial sparing of major salivary glands that
can potentially reduce the incidence, duration, and sever-
ity of xerostomia with a positive impact on health-related
QOL [12-15]. Parotid gland sparing can be further aug-
mented using in-room image-guidance and periodic
adaptive replanning during a course of fractionated
radiotherapy [16]. With conformal techniques, individual
salivary glands may be differentially spared, depending
upon their proximity to high-risk areas. Thus, it is
important to assess their functional status individually
rather than as a whole as is typically assessed by whole-
mouth measurements. Dynamic salivary gland scintig-
raphy using 99mTc-pertechnate is a simple, reproducible,
and minimally invasive test that provides quantitative
estimates of parenchymal and excretory function ofindividual major salivary glands [17]. It can be a suitable
alternative to salivary flow-rate measurements for quanti-
fication of post-radiotherapy salivary dysfunction.
Aims
To report on prospective longitudinal assessment of
functional changes in parotid glands using dynamic
quantitative 99mTc-pertechnate scintigraphy and estimate
their dose–response relationship in a cohort of patients
with HNSCC treated using parotid-sparing conformal
radiotherapy techniques with or without platinum-based
concurrent systemic chemotherapy.
Materials and methods
Sixty previously untreated patients with early to moder-
ately advanced squamous cell carcinoma of the orophar-
ynx, larynx, or hypopharynx (stage T1-T3, N0-2b) were
accrued and treated on an institutional review board
approved prospective randomized controlled trial com-
paring 3D-CRT and IMRT. Suitable patients with loco-
regionally advanced disease (bulky T2, T3, and/or
node positive) also received concurrent chemotherapy.
Cisplatin was administered once weekly as an intravenous
infusion @30 mg/m2 with appropriate hydration, forced
saline dieresis, and anti-emetic prophylaxis as per contem-
porary institutional standard of care. All patients provided
written informed consent for participation in this mono-
institutional randomized trial registered at Clinical Trials
Registry-India (CTRI/2008/091/000045). Physician-rated
acute salivary gland toxicity was the primary endpoint,
while patterns of failure, loco-regional control, disease-
free survival, overall survival, QOL, and late xerostomia
were secondary endpoints. Details on target volume delin-
eation, treatment planning, and delivery have been pub-
lished previously [18,19]. Salivary gland toxicity (both
acute and late xerostomia) was scored subjectively by the
treating physicians using Radiation Therapy Oncology
Group (RTOG) toxicity criteria [20].
Salivary scintigraphy
All patients underwent salivary gland scintigraphy
using 99mTc-pertechnate prior to initiation of definitive
(chemo)radiotherapy. During the initial part of the study,
scintigraphy was done using a semi-quantitative method-
ology, precluding accurate quantification of salivary
function. Subsequently, dynamic quantitative 99mTc-
pertechnate scintigraphy was performed according to the
method described by Klutman [17] in the remaining 41
patients (82 parotid glands) that constitute the dataset of
this analysis. Quantitative assessment of the salivary func-
tion was performed at baseline (pre-treatment) and subse-
quently longitudinally at pre-specified time-points on
follow-up viz. 3-months (n = 41); 12-months (n = 38); 24-
months (n = 35); and 36-months (n = 32) after completion
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were performed with the patient in the supine position
under a gamma-camera (Infinia Hawkeye, GE Healthcare,
Waukesha, USA) with low-energy high-resolution collima-
tors. No oral stimulus was permitted for 60 minutes before
imaging. After intravenous administration of 15 mCi
(200 MBq) 99mTc-pertechnetate, 30-second sequential
frames (anterior view) were acquired and stored in the
computer system. Fifteen minutes after injection, salivary
stimulation was provided by ingestion of 5 ml of sialogogue
(lemon juice). The study was continued for another 10 mi-
nutes after sialogogue administration. For analysis of the
data, regions of interest were drawn around the right and
left parotid and submandibular glands by nuclear medicine
physicians and corresponding time-activity curves gener-
ated. Background correction was performed using the mid-
line neck region. Time-activity curves were fitted to
exponential functions. Salivary excretion fraction (SEF) of
an individual salivary gland was quantified by calculatingFigure 1 Reframed dynamic images (1 minute per frame) showing inc
after sialogogue administration halfway through the study. (a): Region
correction performed using the midline neck region. Typical pre-treatment
steady and progressive increase in uptake immediately following injection
(15-minutes post-injection) leads to decline in detectable counts within the
gland (d). Salivary excretion fraction (SEF) is quantified by calculating maximthe maximal excretory activity per gland as a fraction of
maximal uptake (Figure 1).
Dose–response analysis
For the dose–response analysis, it was assumed that the
glands within an individual patient would not influence
each other. Reduction in salivary gland function after
(chemo)radiotherapy was described by the relative SEF
or SEF ratio defined as the ratio of SEF at time-point‘t’
after treatment compared to the baseline SEF (pre-treat-
ment) x 100%. SEF ratios at different time-points on
follow-up (3, 12, 24, and 36-months) were correlated
with mean parotid doses. An SEF ratio <45% [21] was
used as an objective scintigraphic criteria to define se-
vere salivary toxicity. This has been shown to correlate
best with salivary flow-rate measurements [21] wherein
flow-reduction to <25% of pre-treatment output is
regarded as severe salivary gland toxicity. Dose–response
analysis was restricted to individual parotid glands inreasing uptake in the salivary glands and subsequent washout
s of interest drawn around major salivary glands (b) with background
time-acitivty curves (c) for right and left parotid glands. Note the
of 99mTc-pertechnate. Stimulation of salivary secretion by sialogogue
glands. Percentage uptake and relative uptake of individual parotid
al excretory activity per gland as a fraction of its maximal uptake (d).
Table 1 Demographic and treatment characteristics of
















American Joint Committee on Cancer (AJCC) staging:
Stage II 09 (21.9%)
Stage III 17 (41.5%)
Stage IV 15 (36.6%)
Radiotherapy technique:
Three-Dimensional Conformal Radiotherapy (3D-CRT) 20 (48.8%)
Intensity-Modulated Radiation Therapy (IMRT) 21 (51.2%)
Median (inter-quartile range) of mean parotid dose:
Ipsilateral parotid 50.0 Gy (36.2-59.7)
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for such analyses as they had neither been contoured
nor given any dose-volume constraints during radiother-
apy planning and optimization. Data were fitted to the
Lyman-Kutcher-Burman (LKB) model [22,23] for calcu-
lating normal tissue complication probability (NTCP).
Briefly, this model assumes that the probability of com-
plications after uniform irradiation of a specified partial
volume of an organ follows a sigmoid dose–response re-
lationship. Three parameters in this model are ‘n’, ‘m’,
and tolerance dose 50 (TD50). The parameter ‘n’ ac-
counts for the volume effect of an organ and was con-
sidered as 1 for the purpose of this analysis assuming
parallel architecture of the parotid glands. The param-
eter ‘m’ describes the slope of the dose–response curve.
The TD50 of partial volume ‘v’ is the dose resulting in
50% probability of a complication for uniform irradiation
of that partial volume ‘v’. The model requires input of a
single parotid gland dose. The multi-step dose-volume
histogram (DVH) was transformed to a single-step DVH
with an effective partial volume irradiated uniformly by
a reference dose. The inputs to the model were trans-
formed DVH and parotid gland function that was ad-
justed as a binary response variable on the basis of each
individual gland. A maximum likelihood method was
used to fit the model to the complication data and find
the best estimate and 95% confidence intervals (95% CI)
for the model parameters. In an exploratory analyses,
dose–response curves were also generated to estimate
TD50 values and the corresponding slope (m) using dif-
ferent SEF ratios to define severe salivary gland toxicity
(ranging from SEF ratio <75% to <25%). Agreement be-
tween subjective xerostomia scores (RTOG grading) and
objective scintigraphic criteria (SEF ratio <45%) was
tested using the kappa statistic.
Results
Relevant demographic, clinical, and dosimetric charac-
teristics of the study cohort (n = 41) are described in
Table 1. The mean and standard deviation (SD) of mean
doses to ipsilateral and contralateral parotid glands were
48.3Gy (13.0) and 39.7Gy (12.8) respectively. With IMRT,
the median and its inter-quartile range (IQR) of mean
doses to the ipsilateral parotid gland was 37.2Gy (30.4-
49.0Gy) compared to 59.3Gy (51.2-63.8Gy) with 3D-CRT
(p < 0.001). The contralateral parotid gland was also spared
significantly with IMRT. The median of mean doses with
its IQR to the contralateral parotid gland was 28.1Gy
(25.2-30.4Gy) with IMRT which was significantly lesser
than 53.3Gy (43.8-56.4Gy) with 3D-CRT (p < 0.0001).
The pre-treatment (baseline) SEF was normally dis-
tributed for both parotid glands with a mean value of
50.1% (SD = 14.1). However, considerable variability of
parotid gland output was noted with baseline SEFsranging from 10-70%. No significant pre-treatment dif-
ferences were found between the right and left parotid
gland SEFs. Baseline scintigraphic parameters were not
dependent on age, gender, or stage. The parenchymal as
well as the excretory function of all major salivary glands
was significantly affected by (chemo)radiotherapy with
resultant decrease in SEF ratios at 3-months following
completion of therapy. At 12-months post-treatment,
there was modest functional recovery of the parotid
glands (contralateral > > ipsilateral), which improved
progressively further till 24-months, but reached a plat-
eau somewhat thereafter. The median SEF ratios (IQR)
of the parotid glands were 25.7% (0–55.8%), 38.2%
(3.8-68.9%), 59.0% (8.4-83.6%), and 65.3% (29.4-95.4%) at
3-months, 12-months, 24-months and 36-months respect-
ively (Figure 2) after (chemo)radiotherapy indicating sub-
stantial recovery of salivary function over time, mostly
within the first two years on follow-up.
Figure 2 Boxplot showing median salivary excretion fraction (SEF)
ratios at 3-months, 12-months, 24-months, and 36-months after
(chemo) radiotherapy. Note the moderate recovery of salivary
function continuing till 2-years post-treatment.
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between SEF ratios and mean parotid doses at 3-months
(r = −0.589, p < 0.001); 12-months (r = −0.554, p < 0.001);
24-months (r = −0.371, p = 0.002); and 36-months
(r = −0.350, p = 0.005) respectively (see online Additional
file 1: Table S1). Using a post-treatment SEF ratio <45% as
the scintigraphic criteria to define severe salivary gland
toxicity [21], the estimated TD50 (95% CI) values for the
parotid glands at 3-months, 12-months, 24-months, and
36-months were 35.1Gy (23.6-42.6Gy), 41.3Gy (34.6-
48.8Gy), 55.9Gy (47.4-70.0Gy) and 64.3Gy (55.8-70.0Gy)
respectively (Figure 4a-d). The upper limits of the 95% CI
of TD50 estimates at 24 and 36 months could not be com-
puted accurately, as the dose–response curves lost some of
their sigmoidal nature and became somewhat flatter over
time. The corresponding ‘m values (slope of the dose–
response curve) were 0.48, 0.38, 0.44, 0.38 for the four
time-points respectively. Using the Quantitative Analysis
of Normal Tissue Effects in the Clinic (QUANTEC) 20/20
rule [7], the incidence of severe toxicity (SEF < 45%) was
estimated at 23% at 3-months, but decreased to 13% and
9% at 12-months and 24-months respectively, providing
external validation of the QUANTEC guidelines in predict-
ing a low probability of severe xerostomia. There was poor
to weak agreement between subjective scores (physician-
rated RTOG salivary gland toxicity) and objective scinti-
graphic criteria (toxicity defined as SEF ratio <45%) at
all four post-treatment time-points (see online Additional
file 2: Table S2). Results of the exploratory analyses
estimating the TD50 values and the slope (m) of the dose–
response curve at all four time-points using different SEF
ratios to define severe salivary gland toxicity are also sum-
marized (see online Additional file 3: Table S3).Discussion
Curative-intent radiotherapy for head-neck cancers often
leads to irreversible impairment of salivary function and
consequent xerostomia that adversely affects health-
related QOL [3-5]. This decline in salivary function oc-
curs even after parotid-sparing conformal radiotherapy
albeit to a lesser degree (both in terms of incidence and
severity) particularly with IMRT [19] with substantial re-
covery over time. The use of IMRT in clinical practice
has resulted in improved tolerance to treatment [24] for
patients with head-neck cancer and reduced delayed or
late effects. Dose–response relationship for major
salivary glands has traditionally been based on salivary
flow-rate measurements [9-11]. In particular, a strong
correlation has been shown between the mean parotid
dose and residual post-radiotherapy salivary function [7].
There is a gradual decrease in salivary flow with increas-
ing mean parotid dose. Minimal functional impairment
occurs at mean doses <10-15 Gy, increasing doses (in
the range of 20-30Gy) leads to progressive deterioration
with severe xerostomia occurring at mean parotid doses
of >40Gy. The TD50 for the endpoint of severe xerosto-
mia (traditionally defined as reduction in salivary flow
rate to <25% of pre-treatment value) has been quite vari-
able with estimates ranging from 20–45 Gy [7].
Eisbruch et al. [9] described a steep dose–response re-
lationship for the parotid glands in a cohort of 88 pa-
tients treated with IMRT with estimated 1-year TD50 of
28Gy using salivary flow-rate measurements. Using simi-
lar methodology, Chao et al. [10] also reported a TD50
of 32Gy. In contrast, Roesink et al. [11] found no thresh-
old dose in 108 patients of head-neck cancer treated
with conventional techniques but reported a TD50 of
39Gy at 1-year using flow-data. The largest dataset
of parotid gland function measurements at 1-year
(combining the Michigan and Utrecht experience) re-
ported a TD50 of 39.9 Gy and a complication prob-
ability of 17-26% with mean parotid doses in the range of
25–30 Gy [25].
While flow-rate measurements have remained the
benchmark for assessment of salivary function, given
their limitations, dynamic quantitative pertechnate scin-
tigraphy has emerged as a simple, reproducible, and
minimally invasive test for quantification of post-
radiotherapy salivary function of individual major saliv-
ary glands. Unlike, salivary flow-rate measurements,
there has been a lack of consensus on the definition of
severe salivary toxicity using scintigraphic criteria. In the
largest scintigraphic dataset (n = 96), Roesink et al. [21]
reported significant correlation between SEF ratios
and mean parotid doses, both in early (6-weeks) and
later (1-year) follow-up. They also modeled the dose–
response curves using different SEF ratios to define
severe salivary toxicity due to relative lack of previous
Figure 3 Salivary excretion fraction (SEF) ratio as a function of mean parotid dose at 3-months (a), 12-months (b), 24-months (c), and
36-months (d) respectively. Note the significant inverse correlation between the two at all time-points.
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salivary toxicity defined as SEF ratio <45% gave TD50 esti-
mates that were comparable to their flow-data at 6-weeks
and 1-year after treatment. The Heidelberg group has
consistently used SEF ratio <50% to define severe salivary
toxicity and TD50 (95% CI) estimates for the parotid gland
of about 35Gy (95% CI = 20-45Gy) between 2–6 months
post-treatment [26-28]. Recent times have witnessed
more widespread use of salivary scintigraphy for post-
radiotherapy assessment of salivary dysfunction. The esti-
mated tolerance doses for the parotid gland in selected
studies [21,26-31] using quantitative salivary scintigraphy
are summarized in Table 2. The reported variability in
scintigraphy-based TD50 values is somewhat lesser com-
pared to flow-based estimates. Also scintigraphy-based
TD50 estimates have generally tended to be higher than
their flow-based counterparts. At this point, salivary
scintigraphy cannot be considered superior to salivary
flow-rate measurements, but can be a viable practical al-
ternative. The reported variation in reported TD50 values
(both for salivary flow data as well as scintigraphic data)
could be a result of differences in radiotherapy techniques
and resultant dose distributions, fraction-size effects,
intra-gland sensitivity, use of concurrent chemotherapy,
methods of measurement, definition of toxicity, time-
points of assessment, and NTCP models used for suchcalculation. Semenenko and Li [32] in a pooled analysis of
published clinical data to provide population LKB-NTCP
model parameters for incorporation in treatment planning
estimated a TD50 (95% CI) of 31.4Gy (29.1-34.0Gy) for
the endpoint of reduction in stimulated salivary flow
below 25% within six months after radiotherapy.
Strengths and limitations
The TD50 (95% CI) estimates for the parotid glands in
this study were derived from a prospective cohort of pa-
tients. Hence they do not suffer from inherent limita-
tions of any retrospective analyses. The relatively wide
dispersion of mean parotid doses in the study allowed
for more robust curve fitting at both ends of the
spectrum. Serial follow-up provided an opportunity to
estimate longitudinal recovery of salivary function over
time and calculate TD50 values at longer follow-up
times (2 and 3-years) than is generally reported in the
literature (typically up to 1-year). However, the dose–
response curves became somewhat flatter over time
precluding accurate computation of the upper limits of
the 95% CIs of the TD50 estimates at 24 and 36-months.
Dose–response analyses was restricted to parotid glands
only in the study thereby precluding such modeling for
submandibular salivary glands which are the major con-
tributors to salivation in the resting state. Intentional
Table 2 Studies estimating tolerance dose 50 (TD50) of parotid glands using salivary scintigraphy




Salivary scintigraphy criteria for
defining severe xerostomia
Tolerance Dose 50 (95% CI)
6 weeks-6 months 1-year
#Roesink [21] 96 (conv) 33.14Gy SEF ratio <45% 29Gy (25-34Gy) 43Gy (37-51Gy)
Munter [26] 18 (IMRT) NR SEF ratio <50% 34.8Gy (27.6-42Gy) NR
Munter [27] 33 (conv) 60.6Gy SEF ratio <50% 36.4Gy (20.5-42.3Gy) NR
19 (IMRT) 27.7Gy SEF ratio <50% 35Gy (28-42Gy)
*Rudat [28] 34 (conv) 60.7Gy SEF ratio <50% NR 51.1Gy (43.5-58.7Gy)
31 (IMRT) 30.9Gy
Tenhunen [29] 20 (IMRT) 27.6Gy SEF ratio <50% 40.3Gy (30–53.6Gy) 39.2Gy (27.9-50.2Gy)
Kapanen [30] 25 (IMRT) 23.2Gy SEF ratio <50% 30.4Gy (23.2-37.6Gy) NR
Chen [31] 31 (IMRT) 51.7Gy IL SEF ratio <45% NR 43.6Gy (41.3-45.9Gy)
36.7Gy CL
Present study 41 (3D-CRT and IMRT) 48.3Gy IL SEF ratio <45% 35.1Gy (23.6-42.6Gy) 41.3Gy (34.6-48.8)
39.7Gy CL
CI = confidence interval; SEF = salivary excretion fraction; conv = conventional; 3D-CRT = three dimensional conformal radiotherapy; IMRT = intensity modulated
radiation therapy; NR = not reported; IL = ipsilateral; CL = contralateral.
#First report correlating salivary flow measurements with scintigraphic dataset; SEF ratio <45% best correlated with flow data becoming the benchmark
scintigraphic criteria defining severe xerostomia.
*Updated results from previous publication (ref) reporting delayed xerostomia; conventional radiotherapy plus amifostine group has been excluded from
these estimates.
Figure 4 Fitted dose–response curves for normal tissue complication probability of severe xerostomia (defined as SEF ratio <45%) as a
function of mean parotid dose at 3-months (a), 12-months (b), 24-months (c), and 36-months (d) respectively. Upper and lower curves
represent 95% confidence intervals for the fitted model.
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to better preservation of salivary function without any in-
creased risk of marginal failure in the vicinity of the spared
gland [33]. Vast majority of patients in the study also
received concurrent weekly cisplatin that could pos-
sibly influence salivary toxicity. Although cisplatin
alone per se does not cause significant salivary dysfunc-
tion, its use as a sensitizer concurrently with radiotherapy
increases biologically delivered doses potentially enhan-
cing radiotherapy-induced salivary gland toxicity. In
addition to physician-rated xerostomia, salivary scintig-
raphy was used as an objective test to quantify post-
radiotherapy salivary dysfunction. However, this study
did not use salivary-flow measurements generally consid-
ered the benchmark for such quantification. Lack of con-
sensus criteria for defining severe salivary toxicity using
scintigraphy was another limitation of the study. Never-
theless, various SEF ratio cut-offs were used to define
salivary toxicity in an exploratory analyses, although
SEF <45% was used in the final analysis, interpret-
ation, and reporting. What is also reassuring is that
the TD50 estimates (particularly at 1-year) obtained in
this study are pretty similar to previously published data
of salivary scintigraphy. Although, patients filled QOL
forms at baseline and serially longitudinally on follow-up,
a xerostomia-specific questionnaire was not used in this
study to assess patient-reported outcomes (self-rated
xerostomia). Finally, there was poor to weak agreement
between subjective xerostomia scores and objective
scintigraphic criteria suggesting that observer-based
monitoring may underestimate actual xerostomia man-
dating the need for patient-reported outcomes for such
estimation. Large variability in salivary gland function be-
tween patients, poor correlation between objective and
subjective assessment of salivary toxicity, and limitations
of statistical modeling make accurate prediction of saliv-
ary dysfunction in an individual patient difficult and
challenging.
The tolerance dose estimates for different measures
used to describe high-grade xerostomia viz. salivary
flow-rates, observer-rated subjective xerostomia, and
patient-reported QOL outcomes on a xerostomia-specific
questionnaire can be very different. Miah and colleagues
[34] reported increasing TD50 values from parotid
flow-rates (23.4Gy), subjective xerostomia (33.3Gy),
RTOG-graded subjective xerostomia (42.9Gy), and patient-
reported QOL outcomes (51.6Gy). In the largest analysis
(n = 237 patients) using patient-reported QOL data of
moderate to severe xerostomia [35], the fitted dose–
response curves (LKB-NTCP model) yielded a TD50 of
37.8Gy and 43.9Gy at 3-months and 1-year respectively.
Reassuringly, another study [36] that used patient-reported
QOL outcomes for fitting to the dose–response curve for
NTCP of incidence of ≥ grade 3 xerostomia reported aTD50 of 44.1Gy for the parotid glands 1-year after radio-
therapy which was very similar to their TD50 value of
43.6Gy [31,36] estimated using salivary scintigraphy (SEF
ratio <45%).
Conclusions
Xerostomia remains an important toxicity following
curative-intent irradiation of head-neck cancers. There is
consistent and significant decline in parotid gland function
even after conformal radiotherapy, albeit to a lesser degree,
particularly with IMRT, compared to conventional radio-
therapy. However, parotid gland function recovers moder-
ately on longer follow-up, as evidenced by progressively
higher SEF ratios and TD50 values over time. Dynamic
99mTc-pertechnate scintigraphy is a simple, reproducible,
and minimally invasive test of major salivary gland function
that may be a suitable alternative to salivary flow-rate mea-
surements in clinical practice for quantification of post-
radiotherapy salivary dysfunction.
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